Human ESC-derived MSCs outperform bone marrow MSCs in the treatment of an EAE model of multiple sclerosis.

Abstract

Current therapies for multiple sclerosis (MS) are largely palliative, not curative. Mesenchymal stem cells (MSCs) harbor regenerative and immunosuppressive functions, indicating a potential therapy for MS, yet the variability and low potency of MSCs from adult sources hinder their therapeutic potential. MSCs derived from human embryonic stem cells (hES-MSCs) may be better suited for clinical treatment of MS because of their unlimited and stable supply. Here, we show that hES-MSCs significantly reduce clinical symptoms and prevent neuronal demyelination in a mouse experimental autoimmune encephalitis (EAE) model of MS, and that the EAE disease-modifying effect of hES-MSCs is significantly greater than that of human bone-marrow-derived MSCs (BM-MSCs). Our evidence also suggests that increased IL-6 expression by BM-MSCs contributes to the reduced anti-EAE therapeutic activity of these cells. A distinct ability to extravasate and migrate into inflamed CNS tissues may also be associated with the robust therapeutic effects of hES-MSCs on EAE.

• Authors: Xiaofang Wang, Erin A Kimbrel, Kumiko Ijichi, Debayon Paul, Adam S Lazorchak, Jianlin Chu, Nicholas A Kouris, Gregory J Yavanian, Shi-Jiang Lu, Joel S Pachter, Stephen J Crocker, Robert Lanza, Ren-He Xu
• Journal: Stem cell reports (Stem Cell Reports) Vol. 3 Issue 1 Pg. 115-30 (Jul 08 2014) ISSN: 2213-6711 [Print] United States
• PMID: 25068126 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)

Topics

• Animals
• Bone Marrow Cells (cytology)
• Central Nervous System (pathology)
• Disease Models, Animal
• Embryonic Stem Cells (cytology)
• Encephalomyelitis, Autoimmune, Experimental (therapy)
• Humans
• Mesenchymal Stem Cell Transplantation
• Mesenchymal Stem Cells (cytology)
• Mice
• Multiple Sclerosis (pathology, therapy)